Form 4: Pyxis Oncology CEO Lara Sullivan Acquires Stock Options

Lara Sullivan, CEO of Pyxis Oncology, acquired stock options for 918,308 shares at an exercise price of $0.98 on March 31, 2025.

Summary

• Lara Sullivan, the President, CEO, and CMO of Pyxis Oncology, acquired stock options on March 31, 2025.
• The transaction involved the acquisition of options to purchase 918,308 shares of Pyxis Oncology's common stock at an exercise price of $0.98 per share.
• The options vest over four years, with 25% vesting on March 31, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued employment.
• Following the transaction, Sullivan directly owns options for 918,308 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice that aligns management's interests with shareholders. The vesting schedule suggests a long-term commitment.

Positives

• The acquisition of stock options by the CEO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment and performance from the CEO.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech industry where long-term growth and innovation are key.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Vesting schedules of four years with a one-year cliff are also typical to ensure long-term commitment.
• The specific number of shares and exercise price would be determined based on the company's valuation and compensation strategy, and would be comparable to grants made to executives at similar stage biotech companies such as Arcus Biosciences, or Relay Therapeutics.

Stakeholder Impact

• Shareholders: The stock option grant aligns the CEO's interests with those of the shareholders, incentivizing her to increase shareholder value.
• Employees: The grant could have a positive impact on employee morale, as it demonstrates the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, insider trading, Lara Sullivan, Pyxis Oncology, PYXS, CEO, equity